Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM

被引:0
|
作者
Kalwak, Krzysztof [1 ]
Moser, Laura M. [2 ]
Poetschger, Ulrike [3 ]
Bader, Peter [2 ]
Kleinschmidt, Katharina [4 ]
Meisel, Roland [5 ]
Dalle, Jean-Hugues [6 ]
Yesilipek, Akif [7 ]
Balduzzi, Adriana [8 ,9 ]
Krivan, Gergely [10 ]
Goussetis, Evgenios [11 ]
Staciuk, Raquel [12 ]
Sedlacek, Petr [13 ]
Pichler, Herbert [3 ,14 ]
Svec, Peter [15 ]
Gabriel, Melissa [16 ]
Guengoer, Tayfun [17 ]
Bilic, Ernest [18 ]
Buechner, Jochen [19 ]
Renard, Marleen [20 ]
Vettenranta, Kim [21 ,22 ]
Ifversen, Marianne [23 ]
Diaz-de-Heredia, Cristina [24 ]
Stein, Jerry [25 ,26 ]
Toporski, Jacek [27 ]
Bierings, Marc [28 ]
Peters, Christina [3 ,14 ]
Ansari, Marc [29 ,30 ]
Locatelli, Franco [1 ,31 ]
机构
[1] Wroclaw Med Univ, Dept Pediat Hematol Oncol & Bone Marrow Transplant, Wroclaw, Poland
[2] Goethe Univ Frankfurt, Univ Hosp, Dept Pediat, Div Stem Cell Transplantat & Immunol, Frankfurt, Germany
[3] St Anna Childrens Canc Res Inst, Vienna, Austria
[4] Univ Hosp Regensburg, Dept Pediat Hematol Oncol & Stem Cell Transplantat, Regensburg, Germany
[5] Heinrich Heine Univ, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, Div Pediat Stem Cell Therapy, Dusseldorf, Germany
[6] Univ Paris Cite, Hop Paris Nord, Hematol & Immunol Pediat Unit, Grp Hosp Univ Assistance Publ, Paris, France
[7] Med Pk Antalya Hosp, Antalya, Turkiye
[8] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy
[9] Fdn IRCCS San Gerardo Tintori, Unit Radiodiagnost, Monza, Italy
[10] Cent Hosp Southern Pest, Natl Inst Hematol & Infect Dis, Pediat Hematol & Stem Cell Transplantat Dept, Budapest, Hungary
[11] Agia Sofia Childrens Hosp, Stem Cell Transplant Unit, Athens, Greece
[12] Hosp Pediat Prof Dr Juan P Garrahan, Buenos Aires, Argentina
[13] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic
[14] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol Oncol, Vienna, Austria
[15] Comenius Univ, Natl Inst Childrens Dis, Dept Pediat Hematol & Oncol, Bratislava, Slovakia
[16] Childrens Hosp Westmead, Sydney, NSW, Australia
[17] Univ Childrens Hosp Zurich, Eleonore Fdn & Childrens Res Ctr, Div Hematol Oncol Immunol Gene Therapy & Stem Cell, Zurich, Switzerland
[18] Univ Hosp Ctr, Dept Pediat Zagreb, Div Hematol & Oncol, ZAGREB, Croatia
[19] Oslo Univ Hosp, Dept Pediat Hematol & Oncol, Oslo, Norway
[20] Univ Hosp Leuven, Dept Paediat Oncol, Leuven, Belgium
[21] Univ Helsinki, Helsinki, Finland
[22] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland
[23] Copenhagen Univ Hosp, Rigshospitalet, Dept Pediat & Adolescent Med, Copenhagen, Denmark
[24] Hosp Univ Vall Hebron, Pediat Endocrinol Sect, Barcelona 08035, Spain
[25] Tel Aviv Univ, Petah Tiqwa, Israel
[26] Tel Aviv Univ, Sackler Fac Med, Petah Tiqwa, Israel
[27] Karolinska Univ Hosp, Dept Cellular Therapy Allogene Stem Cell Transpla, Stockholm, Sweden
[28] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[29] Univ Geneva, Fac Med, Dept Pediat Gynecol & Obstet, CANSEARCH Res Platform Pediat Oncol & Hematol, Geneva, Switzerland
[30] Univ Geneva Hosp, Div Pediat Oncol & Hematol, Dept Women Child & Adolescent, Geneva, Switzerland
[31] Osped Pediatr Bambino Gesu, IRCCS, Dept Cardiol, I-00165 Rome, Italy
关键词
STEM-CELL TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; TOTAL-BODY IRRADIATION; LONG-TERM; PEDIATRIC-PATIENTS; REGIMEN; MARROW; TOXICITY; DISEASE; BLOOD;
D O I
10.1182/bloodadvances.2024014548
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The superiority of total body irradiation (TBI)-based vs chemotherapy conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukemia (ALL) has been established in the international, prospective phase- 3 FORUM study, randomizing 417 patients aged 4-18 years in complete remission (CR), who received allo-HSCT from HLA-matched sibling or unrelated donors. Because of the unavailability of TBI in some regions and to accommodate individual contraindications, this study reports the prespecified comparison of outcomes of patients receiving busulfan (BU)- or treosulfan (TREO)-based regimens from 2013 to 2018. Overall, 180 and 128 patients received BU/thiotepa (THIO)/fludarabine (FLU) or TREO/THIO/FLU, respectively. Data were analyzed as of February 2023, with a median follow-up of 4.2 years (range, 0.3-9.1). 3-year overall survival was 0.71 (BU, 95% confidence interval [0.64-0.77]) and 0.72 (TREO, [0.630.79]) and 3-year event-free survival was 0.60 (BU, [0.53-0.67]) and 0.55 (TREO, [0.46-0.63]). The 3-year cumulative incidence of relapse (BU, 0.31 [0.25-0.38]; TREO, 0.36 [0.27-0.44]); and nonrelapse mortality (BU, 0.08 [0.05-0.13]; TREO, 0.09 [0.05-0.15]) were comparable. One case of fatal veno-occlusive disease occurred in each group. No significant differences in acute and chronic graft-versus-host disease (GVHD) or 3-year GVHD-free and relapse-free survival (BU, 0.48 [0.41-0.55]; TREO, 0.45 [0.37-0.54]) were recorded. Outcomes for patients in first and second CR were similar irrespective of the regimen. In conclusion, BU/THIO/FLU or TREO/THIO/FLU regimens can be an alternative to TBI for patients with ALL aged >4 years with contraindications or lack of access to TBI. This trial was registered at www. ClinicalTrials.gov as #NCT01949129.
引用
收藏
页码:741 / 751
页数:11
相关论文
共 47 条
  • [1] Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial
    Kalwak, Krzysztof
    Bader, Peter
    Dalle, Jean-Hugues
    Sedlacek, Petr
    Buechner, Jochen
    Ifversen, Marianne
    Svec, Peter
    Stein, Jerry
    Gungor, Tayfun
    Toporski, Jacek
    Diaz De Heredia, Cristina
    Bierings, Marc
    Meisel, Roland
    Ansari, Marc
    Balduzzi, Adriana
    Poetschger, Ulrike
    Peters
    Locatelli, Franco
    BLOOD, 2023, 142
  • [2] Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia
    Heidrun Boztug
    Marco Zecca
    Karl-Walter Sykora
    Paul Veys
    Arjan Lankester
    Mary Slatter
    Roderick Skinner
    Jacek Wachowiak
    Ulrike Pötschger
    Evgenia Glogova
    Christina Peters
    Annals of Hematology, 2015, 94 : 297 - 306
  • [3] THE RESULTS OF ALLOGENEIC HSCT AFTER TREOSULFAN-BASED CONDITIONING REGIMEN IN CHILDREN WITH AML: MULTICENTER RETROSPECTIVE STUDY OF THE POLISH PEDIATRIC STUDY GROUP FOR HSCT
    Sobkowiak-Sobierajska, Agnieszka
    Zajac-Spychala, Olga
    Deregowski, Maksymilian
    Mielcarek-Siedziuk, Monika
    Kalwak, Krzysztof
    Zaucha-Prazmo, Agnieszka
    Drabko, Katarzyna
    Debski, Robert
    Styczynski, Jan
    Gozdzik, Jolanta
    Wachowiak, Jacek
    BONE MARROW TRANSPLANTATION, 2024, 59 : 264 - 265
  • [4] Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia
    Boztug, Heidrun
    Zecca, Marco
    Sykora, Karl-Walter
    Veys, Paul
    Lankester, Arjan
    Slatter, Mary
    Skinner, Roderick
    Wachowiak, Jacek
    Poetschger, Ulrike
    Glogova, Evgenia
    Peters, Christina
    ANNALS OF HEMATOLOGY, 2015, 94 (02) : 297 - 306
  • [5] Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience
    Morillo-Gutierrez, Beatriz
    Beier, Rita
    Rao, Kanchan
    Burroughs, Lauri
    Schulz, Ansgar
    Ewins, Anna-Maria
    Gibson, Brenda
    Sedlacek, Petr
    Krol, Ladislav
    Strahm, Brigitte
    Zaidman, Irina
    Kalwak, Krzysztof
    Talano, Julie-An
    Woolfrey, Ann
    Fraser, Chris
    Meyts, Isabelle
    Mueller, Ingo
    Wachowiak, Jacek
    Bernardo, Maria Ester
    Veys, Paul
    Sykora, Karl-Walter
    Gennery, Andrew R.
    Slatter, Mary
    BLOOD, 2016, 128 (03) : 440 - 448
  • [6] Gonadotoxicity after Treosulfan-based Myeloablative Conditioning Regimen for Allogeneic HSCT in Girls with Leukemia
    Kostareva, Irina
    Skvortsova, Yuliya
    Iliina, Elena
    Radlevich, Nataliya
    Papusha, Lyudmila
    Balashov, Dmitriy
    Livshits, Anna
    Abrosimov, Andrey
    Shelikhova, Larisa
    Shasheleva, Darya
    Voronin, Kirill
    Maschan, Michael
    Maschan, Aleksey
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 620 - 621
  • [7] Successful allogeneic HSCT after treosulfan-based conditioning in two children with PNH: single-center experience
    Pieczonka, A.
    Skalska-Sadowska, J.
    Sobkowiak-Sobierajska, A.
    Wachowiak-Szajdak, K.
    Tomaszewska, R.
    Szczepanski, T.
    Wachowiak, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S244 - S244
  • [8] Late effects after treosulfan-based conditioning for allogeneic HSCT in children with hematologic malignancies: a single-center experience
    Skvortsova, Yulia
    Shipitsina, Irina
    Balashov, Dmitrij
    Trakhtman, Pavel
    Blagonravova, Oksana
    Persiantseva, Marina
    Skorobogatova, Elena
    Papusha, Lyudmila
    Gutovskaya, Elena
    Shelikhova, Larisa
    Kurnikova, Elena
    Voronin, Kirill
    Maschan, Michail
    Maschan, Alexej
    BONE MARROW TRANSPLANTATION, 2018, 53 : 345 - 346
  • [9] Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party
    J Wachowiak
    K-W Sykora
    J Cornish
    A Chybicka
    J R Kowalczyk
    E Gorczyńska
    M Choma
    G Grund
    C Peters
    Bone Marrow Transplantation, 2011, 46 : 1510 - 1518
  • [10] Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party
    Wachowiak, J.
    Sykora, K-W
    Cornish, J.
    Chybicka, A.
    Kowalczyk, J. R.
    Gorczynska, E.
    Choma, M.
    Grund, G.
    Peters, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 (12) : 1510 - 1518